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Feasibility of endometrial sampling by
vaginal tampons in women with Lynch
syndrome
Jorien M. Woolderink1,2*, Geertruida H. De Bock3, Bettien M. van Hemel4, Erwin Geuken5, Harry Hollema4,
Naomi Werner4 and Marian J. Mourits2
Abstract
Background: Endometrial sampling for the surveillance of women with Lynch syndrome is an invasive and painful
procedure. The aim of this study was to evaluate the feasibility of a less invasive procedure of collecting vital cells
by vaginal tampons.
Methods: This was a prospective feasibility study of women scheduled to undergo annual gynecological
surveillance, including endometrial sampling. We included consecutive asymptomatic women with Lynch syndrome
or first-degree relatives and asked them to insert a vaginal tampon 2–4 h before attending their outpatient
appointment. Feasibility was evaluated by the following metrics: patient acceptance, pain intensity of each
procedure (assessed by visual analog scale; range 0–10), and the presence of vital cells obtained by tampon-based
or endometrial sampling methods. Two pathologists independently evaluated all samples.
Results: In total, 25 of 32 approached women completed the tampon-based procedure, with 23 of these
subsequently undergoing invasive endometrial sampling. The median visual analog scale scores for tampon use
and invasive endometrial sampling were 0 (range, 0–10) and 5.5 (range, 1–10) (p < 0.001). None of the tampon
samples analyzed by cytology showed endometrial cells, but they did contain vital squamous cells and
granulocytes. By contrast, 18 (78%) of the invasive endometrial samples contained enough endometrial tissue for
analysis. No endometrial abnormalities were found by endometrial sampling.
Conclusions: Tampon-based endometrial surveillance was a well-accepted and non-painful procedure, and
although tampons contained vital cells, they did not provide endometrial cells. However, this study was limited to
asymptomatic women with Lynch syndrome (no endometrial pathology), indicating that research is needed to
evaluate whether the tampon method has any utility for endometrial surveillance in women with Lynch syndrome.
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Background
Lynch syndrome (LS) carries a lifetime risk of 10–55% for
endometrial cancer depending on the gene mutation car-
ried [1–7]. The mean age for developing cancer in LS is
50–55 years, which is 10 years younger than in sporadic
cases [3–5, 8]. Women with LS may therefore benefit from
annual surveillance to detect endometrial abnormalities at
premalignant or early malignant stages [8–12]. However,
this has not been shown to improve survival [13].
There is ongoing debate as to whether endometrial
surveillance should be performed by transvaginal ultra-
sound (TVU) with standard endometrial sampling or by
TVU alone, reserving endometrial sampling for when it
is clearly indicated [8, 10–13]. Signs of abnormal peri-
menopausal bleeding can be misinterpreted and endo-
metrial cancer can be missed [14]. The current Dutch
guideline for LS advises annual endometrial surveillance
by TVU plus standard endometrial sampling between
the ages of 40 and 60 years. A major disadvantage of
such sampling is that it is invasive and painful, irrespect-
ive of the indication [15, 16]. An alternative strategy to
avoid this pain is to perform hysteroscopy, typically with
colonoscopy, while under conscious sedation [15, 17,
18]. Given the pain and invasiveness of these procedures,
we wanted to identify an alternative, less painful, and
non-invasive method for collecting endometrial cells.
One option may be to use vaginal tampons.
Obtaining cells from vaginal tampons for diagnosis has
been reported previously for women with cervical can-
cer, high-grade serous ovarian cancer, and endometrial
cancer [19–25]. In 1954, it was first described that ma-
lignant cells could be obtained from tampons used in
women with cervical and endometrial cancer [19, 20].
Much later, in 2004, a study was performed that ana-
lyzed methylated DNA in cervical-vaginal secretions
from women with and without endometrial cancer ob-
tained by tampons [23]. Compared to women without
endometrial cancer (who underwent a hysterectomy for
benign reasons), those with endometrial cancer pre-
sented higher levels of methylated genes in the vaginal
secretions obtained by tampons [23]. Recently, in 2015,
Bakkum-Gamez et al. reported a study of tampon-based
screening for 66 women before hysterectomy for endo-
metrial cancer (n = 38) or benign reasons (n = 28). Gene
level analysis of the tampon samples showed a signifi-
cantly higher methylation rate in women with endomet-
rial cancer compared to women with benign
endometrial abnormalities [25]. None of these existing
studies has reported on the tolerability of tampon use
for cell collection [19–25]. Moreover, studies to date
have only reported the use of tampons in women with
ovarian or cervical malignancies and none has consid-
ered its use for endometrial surveillance in asymptom-
atic women with LS.
In this study, we assessed the feasibility of collecting
endometrial cells with tampons during annual surveillance
in women with LS. The primary aim was to assess whether
tampon use is less painful than the current invasive pro-
cedure of endometrial sampling. The secondary aim was
to evaluate whether it is possible to identify endometrial
cells from tampons in asymptomatic women with LS, and
if so, whether these can be analyzed by a pathologist.
Methods
Study design
This was a prospective pilot study of consecutive women
who underwent annual gynecological surveillance for LS
at either a family cancer clinic (University Medical
Center Groningen) or a gynecology outpatient clinic
(Martini Hospital), Groningen, from January 2017 until
August 2017. Written informed consent was obtained
from all participants. The ethics committee of the Uni-
versity Medical Center in Groningen approved the study.
All relevant data were entered into a separate password-
protected database, and patient identities were protected
by assigning study-specific unique patient numbers.
Inclusion criteria
We included all asymptomatic pre- and postmenopausal
women with LS women (i.e., proven carriers of a patho-
genic mutation in either MLH1, MSH2, MSH6, or
PMS2). We also included first-degree relatives at a 50%
risk of the gene mutation. Participants were required to
have no known endometrial abnormalities at the time of
annual gynecological surveillance.
Collection of endometrial cells by tampon or endometrial
sampling
All women who met the inclusion criteria received writ-
ten information about the study. If they agreed to par-
ticipate, as indicated by the return of a signed informed
consent form, we sent a standard size cotton vaginal
tampon with a 10mL bottle of saline (0.9% NaCl) by
post. Women were asked to insert the tampon vaginally
2–4 h before their surveillance visit. This time frame has
been reported as optimal for obtaining vital cells of suffi-
cient quality for analysis [22, 25]. Women were
instructed to wet the tampon with the 10 mL of saline
before insertion. This was to improve cell adherence to
the outside of the tampon and to prevent cell dehydra-
tion. They were asked not to take a bath or shower after
inserting the tampon.
At the outpatient clinic, the tampon was removed by
the patient and handed to the gynecologist before start-
ing the physical examination. The gynecologist then
immersed the tampon at least ten times in a cytological
fixation fluid and sprayed a ThinPrep® cytology preserva-
tion solution (Hologic, Cytyc Corp., Marlborough, MA,
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USA) along the tampon to collect as many cells as pos-
sible. After removing the tampon, women were asked to
report the pain score for the tampon procedure by visual
analog scale (VAS) score, for which zero indicated no
pain and ten indicated the most severe pain imaginable.
All women were then offered standard gynecological
surveillance consisting of a TVU and subsequent endo-
metrial sampling, for which the VAS score was repeated.
Cytological and histological analysis
The tampon fluid was sent for cytological analysis and
the endometrial sample was sent for independent histo-
logical analysis at a pathology laboratory, without men-
tion of sample inclusion in the tampon study.
One cytological slide was made for each sample of tam-
pon fluid in a ThinPrep® T5000 Processor (Hologic) and
Pap stained. All cytological samples obtained with the tam-
pons were analyzed by an experienced cyto-technician
followed by two cyto-pathologists, and the findings were
described in reports that were compared. The presence and
quality of endometrial cells and the presence or absence of
atypia or endometrial cancer were analyzed in the samples.
Endometrial samples were collected with a Pipelle® for
histological analysis, before hematoxylin and eosin stain-
ing and slide creation. All histopathologic analysis was
done according to standard procedures. The presence or
absence of hyperplasia, with or without atypia or endo-
metrial cancer, was analyzed by two pathologists and the
findings were described in reports that were compared.
All samples were stored in the pathology department.
Data collection
We recorded details of patient characteristics and clin-
ical data for each woman. The clinical data of interest
were parity, age at the surveillance visit, type of gene
mutation, menopause status, use and type of contracep-
tive, date of last menstrual period, endometrial thickness
at TVU, cytopathology reports of tampon samples, and
histopathology reports of endometrial samples. The VAS
scores (range, 0–10) for the tampon procedure and for
standard endometrial sampling were also recorded.
Data analysis
Differences in pain by VAS score between the tampon-
based and endometrial sampling methods were evaluated
by Wilcoxon signed-rank tests. Endometrial cell yield for
both procedures was also assessed. All data analysis was




In total, 32 women received information about the tampon
study. Of these, 25 (78%) accepted and were included in the
analysis, while the remaining 7 (22%) declined to participate
(5 premenopausal and 2 postmenopausal). The characteris-
tics of the 25 participants are summarized in Table 1. The
median age was 47.0 years (range, 37–71 years), 15 (60%)
were premenopausal and 10 (40%) were postmenopausal.
In the premenopausal group, three used oral contracep-
tives, four used a Mirena IUD®, and one used Depo-
Provera. Only one woman in the postmenopausal group
used hormone replacement therapy. The mean endometrial
thicknesses by TVU in the premenopausal and postmeno-
pausal groups were 4.5mm (range, 2–18mm) and 3.0mm
(range, 1–7mm), respectively.
Pain scores for the tampon and endometrial sampling
methods
In total, 25 women underwent tampon-based sampling
and 23 of these progressed to invasive endometrial sam-
pling. The VAS scores for each procedure are summa-
rized in Table 2. The median overall VAS scores were 0
(range, 0–10) for the tampon method and 5.5 (range, 0–
10) for the endometrial sampling method, and the differ-
ence in the level of pain between methods was statisti-
cally significant (p < 0.001). We also compared VAS
scores by menopausal status. Among premenopausal
women, the median VAS score was 0 (range, 0–1) for
the tampon method and 5.0 (range, 3–9) for the endo-
metrial sampling method; the corresponding median
VAS scores in postmenopausal women were 4.5 (range,
0–10) and 5.7 (range, 1–10), respectively.
Cytological and histological analysis
No differences were found in the pathological outcomes
of either the tampon fluid or the endometrial samplings
when comparing the reports of the two pathologists.
The results were again compared by the menopausal sta-
tuses of women and are summarized in Table 2. Of note,
none of the cytological samples obtained with tampons
contained endometrial cells or endocervical cylindric
epithelial cells, although all samples contained vital gran-
ulocytes and squamous cells.
In the premenopausal group, only 13 women (87%)
provided endometrial samples with enough endometrial
tissue for histopathological analysis, and these contained
no endometrial abnormalities. One of the endometrial
samples contained insufficient tissue for analysis and
one woman refused to undergo the procedure because
of severe pain when it was last performed. In the post-
menopausal group, five endometrial samples (50%) con-
tained enough endometrial tissue for histopathological
analysis, but again, none of these revealed endometrial
abnormalities. One woman could not undergo endomet-
rial sampling because of cervical stenosis. In the other
four cases, samples produced insufficient yields. Three
of these cases had an endometrial thickness of 2–3 mm
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and one had an endometrial thickness of 7 mm, but no
further endometrial tissue analysis was performed in this
final case because the woman was asymptomatic.
Discussion
In this feasibility study of an unselected case series of
25 asymptomatic women who underwent annual
gynecological surveillance for LS, tampon use was
well accepted and less painful than invasive endomet-
rial sampling. The median VAS score with the tam-
pon method was 0 compared with 5.5 for standard
endometrial sampling, and this difference was statisti-
cally significant. However, although all tampon-based
samples contained vital cells, no endometrial cells
Table 1 Characteristics of women with LS during endometrial surveillance by tampons and subsequent endometrial sampling
(n = 25)
Overall (n = 25) Premenopausal women (n = 15) Postmenopausal women (n = 10)
Age at study entry, mean (SD) in years 48.8 (9.9) 42.8 (4.3) 57.9 (9.0)
Age at study entry, median (range) in years 47.0 (73–71) 42.0 (37–50) 56.0 (46–71)
Gene mutation
MLH1 3 (12%) 2 (13%) 1 (10%)
MSH2 5 (20%) 3 (20%) 2 (20%)
MSH6 6 (24%) 5 (33%) 1 (10%)
PMS2 5 (20%) 2 (13%) 3 (30%)
Lynch 1 (4%) – 1 (10%)
First degree relative LS 5 (20%) 3 (20%) 2 (20%)
Menopausal state
Premenopausal 15 (60%) 15 (100%) Naa
Postmenopausal 10 (40%) Naa 10 (100%)
Parity
Nulliparous 4 (20%) 2 (13%) 2 (40%)
Primi/multiparous 16 (80%) 13 (87%) 3 (60%)
Unknown 5 5
Hormonal treatment
OC 3 (12%) 3 (20%) –
Mirena IUD 5 (20%) 4 (27%) 1 (10%)
Progesterone 1 (4%) 1 (7%) –
HRTb 1 (4%) – 1 (10%)
None 15 (60%) 7 (47%) 8 (80%)
Endometrial response (mm), Median (range) 3.8 (1–18) 4.5 (2–18) 3.0 (1–7)
1–2 3 (13%) 1 (6%) 2 (22%)
> 2–4 9 (38%) 6 (40%) 3 (33%)
> 4–6 5 (21%) 2 (13%) 3 (33%)
> 6–8 1 (4%) – 1 (11%)
> 8–10 2 (8%) 2 (13%) –
> 10 4 (17%) 4 (27%) –
Unknown 1 – 1
Last period
- < 2 weeks 3 (12%) 3 (21%) –
- ≥ 2 weeks 11 (46%) 11 (79%) –
Postmenopausal 10 (42%) – 10 (100%)
Unknown 1 1 –
aNa not applicable
bHRT hormone replacement therapy
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were collected. This may relate to the fact that women
were asymptomatic and free from endometrial pathology.
Standard endometrial sampling is a painful procedure.
In other research of women with LS and of first-degree
relatives who underwent annual surveillance, the VAS
score for the pain associated with standard endometrial
sampling was 5.0, which is comparable to our result of
5.5 [16]. In the same cohort, 20% of women also decided
to refrain from endometrial sampling because of pain,
opting instead for either preventive surgery or annual
gynecological surveillance by TVU alone [16]. Two other
studies evaluated the utility of combining endometrial
sampling and colonoscopy in women with LS to allow
the procedure to be performed under conscious sed-
ation. They concluded that this combination resulted in
a less painful experience than endometrial sampling
without sedation in a standard office setting [17, 18].
Overall, 78% of the standard endometrial samplings in
the present study contained enough tissue for analysis,
which is consistent with the levels of 74–90% reported
in other studies [26, 27].
All tampon samples in this study contained vital cells.
However, we detected no endometrial cells, which con-
trasts starkly with earlier research [19–25]. The most
plausible explanation for this is that we tested endomet-
rial cells in healthy women rather than in women with
gynecological (pre)malignancies. Indeed, given that we
found no malignancies or endometrial abnormalities, it
is plausible that endometrial cells would not be shed.
To date, studies reporting on the collection of endo-
metrial cells with tampons have compared the yields in
women with and without endometrial cancer. In those
cases, it is found that malignant cells and methylated
DNA were present on vaginal tampons obtained from
women with endometrial cancer [20–23, 25, 28–35].
DNA methylation in cells is a sensitive procedure for
discriminating between women with and without endo-
metrial cancer [23, 25]. Given that DNA methylation as-
says can be performed on cell fragments and do not
require intact cells, they may potentially be more sensi-
tive than the tampon technique used in this study [25].
Other studies found that endometrial cells detected by
cervical smear can be used to indicate endometrial path-
ology, especially when vaginal bleeding is present [36,
37]. However, none of the women in this study had vagi-
nal blood loss during the procedures. Using vaginal tam-
pons to collect cells is a well-accepted procedure, and
although three women in the postmenopausal group re-
ported high VAS scores for the procedure (range, 7–9),
most reported low scores (range, 0–2), and none of the
women in the premenopausal group reported pain. Fur-
ther research is therefore warranted to determine the ap-
plicability of vaginal tampons for surveillance in women at
increased risk of endometrial cancer. Women with LS
have an increased lifetime risk of developing endometrial
cancer, translating to an annual risk of about 2.5%. Given
that standard endometrial sampling is invasive and pain-
ful, with some opting not to undergo surveillance, there is
certainly merit in investigating whether it could be re-
placed by the tampon method. We now require a larger
and longer-term study to clarify the true utility of
tampon-based screening in this cohort [1, 3, 5–7, 38–40].
To the best of our knowledge, no prior study has eval-
uated the feasibility of collecting endometrial cells with
tampons in asymptomatic women. Moreover, we are
aware of no research assessing this procedure in women
with LS. A limitation of the study is that we did not con-
sider whether endometrial abnormalities are identifiable
Table 2 Yield of endometrial cells obtained with tampons and standard endometrial sampling
Tampons (n = 25) (%) Endometrial sampling (n = 25) (%)
Median VAS score (range) 0.0 (0–10) 5.5 (1–10)
Premenopausal women 0.0 (0–2) 5.0 (3–9)
Postmenopausal women 4.5 (0–10) 7.0 (1–10)
Quality of cells in the samples
- Good 25 (100%) 18 (78%)
- No/To less endometrial cells 25 (100%) 5 (22%)





Sufficient endometrial samples 0 18 (78%)
Premenopausal women – 13 (72%)
Postmenopausal women – 5 (28%)
Insufficient endometrial samples 25 (100%) 5 (23%)
Premenopausal women 15 (60%) 1 (20%)
Postmenopausal women 10 (40%) 4 (80%)
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by the tampon method in symptomatic women with LS.
Another limitation is that DNA methylation in the cells
of the 25 asymptomatic women in this pilot study was
not evaluated. Future research should focus on the op-
portunity to find abnormal endometrial cells by using
tampons in women with endometrial (pre)malignancies.
In conclusion, the tampon procedure is a non-painful
and well-accepted procedure compared with invasive
endometrial sampling during annual gynecological
screening for LS. However, endometrial cells were only
obtained from asymptomatic women with LS. Further
research should now focus on the effectiveness and ap-
plicability of vaginal tampons for identifying endometrial
abnormalities in the annual screening of women with
LS. We advocate that future research should also include
DNA methylation assays as part of the sample analysis.
If tampon use can be shown to be useful for screening
or diagnosis, it could help to avoid painful and invasive
procedures, thereby improving uptake.
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